{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:52:24Z","timestamp":1778903544172,"version":"3.51.4"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To identify soluble biomarkers associated with response to therapy with tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The study was conducted at a PsA clinic where patients are assessed every 6 months, and serum samples are collected and stored once a year at the time of clinical assessment. Forty patients with active PsA who gave serum samples prior to treatment with TNFi and after at least 3 months of therapy were identified. Patients were classified as TNFi responders if tender joint count was &lt; 3, swollen joint count was 0, and Psoriasis Area and Severity Index score was &lt; 4 at the time the second sample was collected. The following biomarkers were tested by ELISA: TNF superfamily 14, matrix metalloprotease-3 (MMP-3), receptor activator of nuclear factor kappa-B ligand, osteoprotegerin, cartilage oligomeric matrix protein (COMP), CPII, C2C and C1-2C, CS-846, and highly sensitive C-reactive protein. Paired t tests and logistic regression was used for statistical analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>After a mean treatment duration of 11 months with TNFi (etanercept 28 patients, adalimumab 6, golimumab 4, infliximab 2), 29 patients were classified as TNFi responders. Baseline level of MMP-3 was independently associated with responder status (OR 1.067 for each 1-unit increase, p = 0.045). A reduction in MMP-3 levels with therapy increased the odds of achieving response (OR 1.213 for each 1-unit change, p = 0.030), whereas a reduction in COMP decreased the odds (OR 0.587, for each 100-unit increase, p = 0.039). None of the other biomarkers was associated with response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Baseline as well as reduction in serum MMP-3 and increase in serum COMP are independently associated with response to TNFi therapy in patients with PsA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.121162","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T04:27:39Z","timestamp":1367468859000},"page":"866-871","source":"Crossref","is-referenced-by-count":54,"title":["Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis"],"prefix":"10.3899","volume":"40","author":[{"given":"Vinod","family":"Chandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy A.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawnda J.","family":"Pellett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Carty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2013,5,1]]},"reference":[{"key":"2018112909313797000_40.6.866.1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"2018112909313797000_40.6.866.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2018112909313797000_40.6.866.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2018112909313797000_40.6.866.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140582"},{"key":"2018112909313797000_40.6.866.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq091"},{"key":"2018112909313797000_40.6.866.6","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"2018112909313797000_40.6.866.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq105"},{"key":"2018112909313797000_40.6.866.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.23104"},{"key":"2018112909313797000_40.6.866.9","first-page":"127","article-title":"Psoriatic arthritis \u2014 clinical and laboratory analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"2018112909313797000_40.6.866.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08628.x"},{"key":"2018112909313797000_40.6.866.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.161"},{"key":"2018112909313797000_40.6.866.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.20696"},{"key":"2018112909313797000_40.6.866.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei208"},{"key":"2018112909313797000_40.6.866.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.22589"},{"key":"2018112909313797000_40.6.866.15","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1443.016"},{"key":"2018112909313797000_40.6.866.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21821"},{"key":"2018112909313797000_40.6.866.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102277"},{"key":"2018112909313797000_40.6.866.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.646"},{"key":"2018112909313797000_40.6.866.19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316069"},{"key":"2018112909313797000_40.6.866.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21896"},{"key":"2018112909313797000_40.6.866.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00056-5"},{"key":"2018112909313797000_40.6.866.22","unstructured":"Poole AR . Cartilage in health and disease. In: Koopman WJ , editor. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001:226\u201384."},{"key":"2018112909313797000_40.6.866.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.9.583"},{"key":"2018112909313797000_40.6.866.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116113"},{"key":"2018112909313797000_40.6.866.25","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J"},{"key":"2018112909313797000_40.6.866.26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1172\/JCI117753","article-title":"Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism","volume":"95","author":"M\u00e5nsson","year":"1995","journal-title":"J Clin Invest"},{"key":"2018112909313797000_40.6.866.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060079"},{"key":"2018112909313797000_40.6.866.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(94)80024-3"},{"key":"2018112909313797000_40.6.866.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0107-0"},{"key":"2018112909313797000_40.6.866.30","doi-asserted-by":"crossref","first-page":"e12556","DOI":"10.1371\/journal.pone.0012556","article-title":"Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo","volume":"5.pii","author":"van Kuijk","year":"2010","journal-title":"PLoS One"},{"key":"2018112909313797000_40.6.866.31","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1528-x"},{"key":"2018112909313797000_40.6.866.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00715.x"},{"key":"2018112909313797000_40.6.866.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2018112909313797000_40.6.866.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110278"},{"key":"2018112909313797000_40.6.866.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100919"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.121162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:25:19Z","timestamp":1543497919000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.121162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,1]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3899\/jrheum.121162"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.121162","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,1]]}}}